Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced the appointment of Suresh Durgam, M.D., to its board of directors, subject to approval by Cboe Canada. Durgam, who previously served on the company scientific advisory board, brings more than 20 years of experience in central nervous system (CNS) drug development, clinical research, and regulatory strategy.
Most recently, Durgam served as executive vice president and chief medical officer of Intra-Cellular Therapies, where he helped secure U.S. Food and Drug Administration approvals for CAPLYTA (R) across multiple indications, including schizophrenia, bipolar depression, and major depressive disorder. His appointment is expected to support Helus Pharma as it advances its CNS pipeline through late-stage development toward potential commercialization.
The addition of a board member with Durgam's regulatory and clinical track record signals Helus Pharma's intent to navigate the complex late-stage development and approval process for its lead candidates. For readers invested in mental health innovation, this could mean faster progress toward new treatment options for depression and anxiety, conditions that affect millions worldwide.
Helus Pharma(TM), the commercial operating name of Cybin Inc., founded in 2019, is committed to helping minds heal by developing proprietary NSAs: synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health.
Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the FDA. It is also developing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. Additionally, the company has an extensive research portfolio of investigational NSAs and operates in Canada, the United States, the United Kingdom, and Ireland.
For company updates and to learn more about Helus Pharma, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom.
MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies, disseminated the announcement. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
For more information, visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
